Gen-Probe Aims For Long-Term Growth With Oncological Assays
This article was originally published in The Gray Sheet
Gen-Probe will continue to devote a quarter of its revenue to research and development in anticipation of entering the oncology and industrial testing markets
You may also be interested in...
Gen-Probe expects an upsurge in revenue from its West Nile Virus blood screening assay shortly after FDA approval, according to CFO and VP-Finance Herm Rosenman
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies